Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People.

Cai-E Song, Yan Wang, Xue-Mei Dai, Hong-Yan Wu
{"title":"Efficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People.","authors":"Cai-E Song, Yan Wang, Xue-Mei Dai, Hong-Yan Wu","doi":"10.2174/0118715303283400240521120048","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The study aimed to investigate the efficacy and safety of semaglutide in weight loss in non-diabetic people.</p><p><strong>Methods: </strong>In this study, 84 non-diabetic people who used semaglutide to lose weight in the outpatient department of our hospital from January 1, 2022, to June 30, 2022, were enrolled and compared for changes in body weight, waist circumference, Body Mass Index (BMI), fasting blood glucose, blood pressure, pulse, and body composition (body fat ratio, visceral fat area, and skeletal muscle) before treatment and 12 weeks after the treatment to analyze the weight loss efficacy and safety.</p><p><strong>Results: </strong>After administering semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously once a week for 12 weeks, 84 participants in this study obtained an average weight loss of 5.91 ± 3.37 kg, equivalent to 6.15 ± 4.28% of baseline body weight, and there was also a significant reduction in visceral fat area and a slight reduction in blood pressure. The most common adverse reactions included gastrointestinal reactions (nausea, vomiting, and diarrhea), which were mild and subsided within 1-2 days. No severe adverse reaction, such as hypoglycemia and hypotension, was observed.</p><p><strong>Conclusion: </strong>Low-dose semaglutide has been found to be effective and safe for short-term weight loss in non-diabetic people.</p>","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715303283400240521120048","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The study aimed to investigate the efficacy and safety of semaglutide in weight loss in non-diabetic people.

Methods: In this study, 84 non-diabetic people who used semaglutide to lose weight in the outpatient department of our hospital from January 1, 2022, to June 30, 2022, were enrolled and compared for changes in body weight, waist circumference, Body Mass Index (BMI), fasting blood glucose, blood pressure, pulse, and body composition (body fat ratio, visceral fat area, and skeletal muscle) before treatment and 12 weeks after the treatment to analyze the weight loss efficacy and safety.

Results: After administering semaglutide 0.25 mg, 0.5 mg, 0.75 mg, or 1 mg subcutaneously once a week for 12 weeks, 84 participants in this study obtained an average weight loss of 5.91 ± 3.37 kg, equivalent to 6.15 ± 4.28% of baseline body weight, and there was also a significant reduction in visceral fat area and a slight reduction in blood pressure. The most common adverse reactions included gastrointestinal reactions (nausea, vomiting, and diarrhea), which were mild and subsided within 1-2 days. No severe adverse reaction, such as hypoglycemia and hypotension, was observed.

Conclusion: Low-dose semaglutide has been found to be effective and safe for short-term weight loss in non-diabetic people.

塞马鲁肽对非糖尿病患者减肥的有效性和安全性
研究目的本研究旨在探讨塞马鲁肽对非糖尿病患者减肥的有效性和安全性:本研究选取2022年1月1日至2022年6月30日在我院门诊使用塞马鲁肽减肥的84例非糖尿病患者为研究对象,比较治疗前和治疗12周后体重、腰围、体重指数(BMI)、空腹血糖、血压、脉搏、身体成分(体脂比、内脏脂肪面积、骨骼肌)的变化,分析减肥的有效性和安全性:这项研究的84名参与者每周一次皮下注射塞马鲁肽0.25毫克、0.5毫克、0.75毫克或1毫克,持续12周后,平均体重减轻了5.91±3.37千克,相当于基线体重的6.15±4.28%,内脏脂肪面积也显著减少,血压略有下降。最常见的不良反应包括胃肠道反应(恶心、呕吐和腹泻),这些反应都很轻微,并在 1-2 天内缓解。未观察到低血糖和低血压等严重不良反应:结论:小剂量塞马鲁肽对非糖尿病患者的短期减肥有效且安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信